{"id":280704,"date":"2018-10-22T22:07:01","date_gmt":"2018-10-22T22:07:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=280704"},"modified":"2018-10-22T22:07:01","modified_gmt":"2018-10-22T22:07:01","slug":"lung-cancer-market-to-rise-to-usd-369298-mn-till-2023-by-treatment-surgery-chemotherapy-radiotherapy-etc-declares-mrfr","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lung-cancer-market-to-rise-to-usd-369298-mn-till-2023-by-treatment-surgery-chemotherapy-radiotherapy-etc-declares-mrfr_280704.html","title":{"rendered":"Lung Cancer Market to Rise to USD 36929.8 Mn. Till 2023 | by treatment Surgery, Chemotherapy, Radiotherapy, etc | Declares MRFR"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Lung Cancer Market”<\/div>\n<\/div>\n<\/div>\n
Market Research Future (MRFR)\u2019s study reveals that the \u201cGlobal Lung Cancer Market\u201d, the report offer detailed Analysis about the Top Trends and Current Scenario with competitive landscape and key regions development status.<\/div>\n

The Global Market of Lung Cancer is expected to reach USD 36929.8 million in 2023 from USD 15219.7 million in 2016 with a CAGR of 13.5% during the forecast period 2017-2023. Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in lung tissue with symptoms such as coughing, weight loss, and fatigue and chest pain. The two types of lung cancers are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). The NSCLC type accounts for almost 80% of the total lung cancers.<\/p>\n

The cure rates for the two types of lung cancers exchange their positions with the SCLC being the most malignant. The cure rates also depend on the stage of cancer detection with rates varying by 55% for first stage to just 1% for stage four.<\/p>\n

Request for Sample Report at <\/strong>https:\/\/www.marketresearchfuture.com\/sample_request\/1185<\/a><\/p>\n

Almost 85% of cases of lung cancer are due to long-term tobacco smoking. Cigarette smoke contains at least 73 known carcinogens. Other factors causing lung cancer are genetic factors and exposure to triggers and carcinogens such as radon gas, asbestos, radioactive materials, second-hand smoke, or air pollution. It has also been demonstrated that passive smokers have a 20–30% increase in risk.<\/p>\n

The treatments for lung cancer include surgery, chemotherapy, and radiotherapy with NSCLC responding better to surgery and SCLC usually responding better to chemotherapy and radiotherapy. Notably, smoking is the primary driver for the rising cases of lung cancer. According to World Health Organization (WHO) tobacco kills more than 7 million people each year of which more than 6 million deaths are the result of direct tobacco use. Lung cancer is the leader with a whopping 37% of deaths. Of more concern is the rising rates of lung cancer due to passive smoking.<\/p>\n

Prominent Players:<\/strong><\/p>\n

Pfizer<\/p>\n

ELI Lilly and Company<\/p>\n

Merck & Co.<\/p>\n

F. Hoffmann-La Roche AG<\/p>\n

Novartis<\/p>\n

Bristol-Myers Squibb<\/p>\n

Sanofi and others.<\/p>\n

Lung Cancer Market – Competitive Analysis<\/strong><\/p>\n

The lung cancer market is currently dominated by various players. Lung cancer has become one of the nost common causes of cancer death worldwide. So, in recent years various existing and new marketers are continuously coming up with innovative products to control this condition.<\/p>\n

Ask Any Questions at <\/strong>https:\/\/www.marketresearchfuture.com\/enquiry\/1185<\/a><\/p>\n

For instance, F. Hoffmann-La Roche Ltd, a Switzerland based company, manufactures various cancer treatment products such as anti-bcl-2 (SP66) Rabbit Monoclonal Primary Antibody, anti-c-MYC (Y69) Rabbit Monoclonal Primary Antibody, anti-CD7 (SP94) Rabbit Monoclonal Primary Antibody, anti-CEA (TF 3H8-1) Primary Antibody, anti-Cytokeratin 5\/6 (D5\/16B4) Mouse Monoclonal Primary Antibody, anti-E-cadherin (EP700Y) Rabbit Monoclonal Primary Antibody, and others. In the year 2013, Roche received FDA approval for Tarceva (erlotinib) tablets and cobas EGFR Mutation Test for specific type of lung cancer.<\/p>\n

Lung Cancer Market – Dynamics<\/strong><\/p>\n